Search
forLearn
5 / 801 resultslearn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
learn 18β-glycyrrhetinic acid
learn GT20029
research compound made to degrade androgen receptors in scalp
learn Grape stem cells
Research
5 / 1000+ resultsresearch Implication of microRNA regulation in para-phenylenediamine-induced cell death and senescence in normal human hair dermal papilla cells
Hair dye ingredient PPD causes cell death and aging in human hair cells by altering microRNA levels.
research The local hypothalamic–pituitary–adrenal axis in cultured human dermal papilla cells
Stress hormone CRF can cause hair loss by affecting hair growth cells and hormones.
research The local hypothalamic–pituitary–adrenal axis in cultured human dermal papilla cells
Stress hormone CRF causes hair loss and stops hair cell growth.
research In Vitro and In Vivo Models for the Development of Hair Growth Materials By Regulating the β-Catenin Signaling Pathways
The research found a way to develop hair growth materials by targeting a specific signaling pathway.
research The local hypothalamic–pituitary–adrenal axis in cultured human dermal papilla cells
Stress hormone CRF causes hair loss and inhibits hair growth in human cells.
Community Join
5 / 1000+ results
community Minoxidil Response Bottlenecks: Why Sulfation and Transport Matter (And Where Tretinoin Fits In)
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hair follicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
community GT20029 Big Phase 2 Update Results!
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
community GT20029 phase II results release date?
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community GT20029 Phase 2 results are out
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.